Its not unreasonable that the PE Ratio for Therma Bright could between 5.0 unto 10.0, based on the growth in these other firms, which DID NOT have Covid-19 Rapid Test products two years ago. These is a brand spanking new product line for all these companies, which includes new revenue streams into their businesses. .
25% of Abbotts $11.5B Revenues was Covid19 tests ($2.8B), so you could estimate that 25% of PE Ratio of 30.6 = 7.5. on Covid alone.
Abbott reported fourth-quarter net income of $1.98 billion on revenues of nearly $11.5 billion, which were up 7%, as worldwide. Abbott’s global Covid-19 testing sales hit $2.3 billion in the fourth quarter and the bulk of that, or $2.1 billion, came from Abbott’s family of rapid tests: BinaxNOW, Panbio and ID NOW.
(Source: Forbes - January 26, 2022: https://www.forbes.com/sites/brucejapsen/2022/01/26/abbott-labs-weve-shipped-14-billion-covid-tests-since-pandemics-beginning/?sh=7e8963d46431)